| 0.7188 -0.331 (-31.54%) | 11-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.5 |
1-year : | 1.98 |
| Resists | First : | 1.28 |
Second : | 1.7 |
| Pivot price | 1.13 |
|||
| Supports | First : | 0.61 |
Second : | 0.51 |
| MAs | MA(5) : | 1.01 |
MA(20) : | 1.19 |
| MA(100) : | 3.06 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 11.6  |
D(3) : | 11.5 |
| RSI | RSI(14): 23 |
|||
| 52-week | High : | 33.65 | Low : | 0.61 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LIMN ] has closed below the lower bollinger band by 23.4%. Bollinger Bands are 86.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for {EMPTY} bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.86 - 0.86 | 0.86 - 0.87 |
| Low: | 0.61 - 0.61 | 0.61 - 0.61 |
| Close: | 0.71 - 0.72 | 0.72 - 0.73 |
Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.
Fri, 21 Nov 2025
Midday Stock Roundup: RxSight up 14% - Orange County Business Journal
Fri, 21 Nov 2025
Liminatus Pharma, Inc. Class A Common Stock (LIMN) -29.6% in Normal Trading: Significant Drop Amid Routine Trading - Stocks Telegraph
Mon, 06 Oct 2025
Liminatus Pharma, Inc. SEC 10-Q Report - TradingView
Thu, 12 Jun 2025
Why Oracle Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Wed, 04 Jun 2025
Liminatus Pharma Stock Surges to Record High After Regaining Nasdaq Compliance - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 79.4 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 378 (K) |
| Shares Short P.Month | 396 (K) |
| EPS | -0.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.35 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -4.5 |
| PEG Ratio | 0 |
| Price to Book value | -2.12 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|